Management

//Management
Management 2019-04-11T14:44:55+00:00
Yaron Pereg

Yaron Pereg

PhD, CEO

Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology and immune-oncology. Heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. Prior to joining KAHR, served as Chief Development Officer at Cellect Biotechnology (APOP) and as Senior Director of Oncology at BioLineRx (BLRX). Prior to that held R&D positions at Genentech, a leading biotechnology company, member of the Roche Group.

Adam Foley-Comer

Adam Foley-Comer

MD, CMO

Drug development professional with over 20 years of clinical and industry experience in Global CRO, big Pharma and Biotechnology companies. Prior to joining KAHR, served as VP Medical Affairs at Immune Pharmaceuticals and as Senior Medical Director at Quark Pharmaceuticals. Prior to that was the Medical Director at BioLineRx and before that worked at Roche and Quintiles developing expertise in the design and conduct of early phase clinical studies.

Ayelet Chajut

Ayelet Chajut

PhD, CTO

Research and development senior specialist with over 20 years of industry experience in innovative Biotechnology companies. Prior to joining KAHR, served as VP of R&D in multiple companies including Pluristem Therapeutics, Rosetta Genomics and Quark Pharmaceuticals Prior to that she was the Director of Science & Technology at Quantomics.

Iris Pecker

Iris Pecker

PhD,  VP CMC

Biopharmaceuticals CMC expert and drug development professional with over 20 years’ experience in process development for the production of therapeutic proteins. Prior to KAHR, served as the head of process development at InSight Biopharmaceuticals.

Rinat Tabakman

Rinat Tabakman

PhD, VP Development

Drug development expert and a pharmacologist-toxicologist by training. Has worked in the innovative pharmaceutical industry for more than a decade. Prior to joining KAHR Medical, served as a Senior Director Preclinical Development in BioLineRx (NASDAQ: BLRX), leading the non-clinical development, for various indications and assets up to marketing and managed leading non-clinical CROs worldwide both for efficacy models as well as for GLP toxicology and PK work.